A focused review on recent advances in diagnosis and management of fibrolamellar hepatocellular carcinoma

Abstract

Fibrolamellar hepatocellular carcinoma (FHCC) is a rare primary malignancy of the liver for which data remain limited. This tumor is more often diagnosed in younger patient populations in the absence of underlying cirrhosis and hepatitis. These lesions can be diagnosed on computed tomography scan or magnetic resonance imaging with common findings including central calcifications, a central stellate scar, and radiating fibrotic bands. Laboratory markers have not proved useful for diagnosis; however, pathologic analysis can be implemented to aid in diagnosis with findings including ample granular eosinophilic cytoplasm, nuclei with open chromatin and prominent macronuclei, hyaline and pale bodies, and dense lamellar fibrosis that divides the cells into cords or trabeculae. FHCC demonstrates aggressive malignant potential with nodal spread. Treatment patterns have remained mainly surgical; however, systemic therapies have been implemented and are under further investigation with clinical trials. Locoregional therapies and radiation therapies have been trialed sparingly. In this focused review, we discuss the most up-to-date perspective on epidemiology, clinical presentation, diagnostic approach, differential diagnosis, treatment regimens, prognosis, and future directions of FHCC.

Keywords

Fibrolamellar hepatocellular carcinoma / diagnosis / treatment / surgery / systemic / histology / review

References

[1] EDMONDSON HA.Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood.AMA J Dis Child1956;91:168-86

[2] Lafaro KJ.Fibrolamellar hepatocellular carcinoma: current clinical perspectives.J Hepatocell Carcinoma2015;2:151-7 PMCID:PMC4918295

[3] Craig JR,Edmondson HA.Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features.Cancer1980;46:372-9

[4] Bosman FT,Hruban RH. WHO classification of tumours of the digestive system. No. Ed. 4. World Health Organization. 2010;

[5] Lim II,LaQuaglia MP.Advances in fibrolamellar hepatocellular carcinoma: a review.Eur J Pediatr Surg2014;24:461-6

[6] El-Serag HB.Is fibrolamellar carcinoma different from hepatocellular carcinoma?.Hepatology2004;39:798-803

[7] Graham RP.Fibrolamellar carcinoma: what is new and why it matters.Surg Pathol Clin2018;11:377-87

[8] Eggert T,Duffy A,Greten TF.Fibrolamellar hepatocellular carcinoma in the USA, 2000-2010: a detailed report on frequency, treatment and outcome based on the surveillance, epidemiology, and end results database.United European Gastroenterol J2013;1:351-7 PMCID:PMC4040774

[9] Ramai D,Lai JK,Adler DG.Fibrolamellar hepatocellular carcinoma: a population-based observational study.Dig Dis Sci2021;66:308-14

[10] Perisetti A,Yendala R,Giorgakis E.Non-cirrhotic hepatocellular carcinoma in chronic viral hepatitis: current insights and advancements.World J Gastroenterol2021;27:3466-82 PMCID:PMC8240056

[11] Houben KW.Liver transplantation for hepatocellular carcinoma in patients without underlying liver disease: a systematic review.Liver Transpl Surg1999;5:91-5

[12] Liu S,Tong J,Wang B.PET-CT scan is a valuable modality in the diagnosis of fibrolamellar hepatocellular carcinoma: a case report and a summary of recent literature.QJM2011;104:477-83

[13] Haratake J,Lee SD.Fibrolamellar carcinoma of the liver in a middle-aged Korean man.J UOEH1990;12:349-54

[14] Hoshino H,Nishimura D.Case report: fibrolamellar hepatocellular carcinoma in a Japanese woman: a case report and review of Japanese cases.J Gastroenterol Hepatol1996;11:551-5

[15] Assi H,Mukherjee S,Vesely S.Clinical characteristics and predictors of outcomes in patients with fibrolamellar carcinoma: an eleven-year analysis of the National Cancer Database (NCDB).JCO2019;37:413-413

[16] Chakrabarti S,Kommalapati A.Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma.J Gastrointest Oncol2019;10:554-61 PMCID:PMC6534717

[17] Wahab MA,El Nakeeb A.Clinicopathological features and surgical outcome of patients with fibrolamellar hepatocellular carcinoma (experience with 22 patients over a 15-year period).World J Gastrointest Surg2017;9:61-7 PMCID:PMC5329705

[18] Andersen JB.Fibrolamellar hepatocellular carcinoma: a rare but distinct type of liver cancer.Gastroenterology2015;148:707-10

[19] Chapuy CI,Sharma R,Kozyreva ON.Hyperammonemic encephalopathy associated with fibrolamellar hepatocellular carcinoma: case report, literature review, and proposed treatment algorithm.Oncologist2016;21:514-20 PMCID:PMC4828114

[20] Muramori K,Taguchi T.High aromatase activity and overexpression of epidermal growth factor receptor in fibrolamellar hepatocellular carcinoma in a child.J Pediatr Hematol Oncol2011;33:e195-7

[21] McDonald JD,Shindorf ML.Elevated serum α-fetoprotein is associated with abbreviated survival for patients with fibrolamellar hepatocellular carcinoma who undergo a curative resection.Ann Surg Oncol2020;27:1900-5 PMCID:PMC8456707

[22] Ang CS,Choti MA.Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium.Gastrointest Cancer Res2013;6:3-9 PMCID:PMC3597938

[23] Yamashita S,Kaseb AO.Prognosis of fibrolamellar carcinoma compared to non-cirrhotic conventional hepatocellular carcinoma.J Gastrointest Surg2016;20:1725-31

[24] Torbenson M.Fibrolamellar carcinoma: 2012 update.Scientifica (Cairo)2012;2012:743790 PMCID:PMC3820672

[25] Morise Z,Mizoguchi Y.Fibrolamellar carcinoma of the liver in a Japanese hepatitis B virus carrier.J Gastroenterol Hepatol2005;20:1136-8

[26] Dadke D,Krishnamurthy S.The detection of HBV antigens and HBx-transcripts in an Indian fibrolamellar carcinoma patient: a case study.Liver2002;22:87-91

[27] Chaudhari VA,Bhandare M.Management of fibrolamellar hepatocellular carcinoma.Chin Clin Oncol2018;7:51

[28] Ganeshan D,Kundra V,Rashid A.Imaging features of fibrolamellar hepatocellular carcinoma.AJR Am J Roentgenol2014;202:544-52

[29] Lin CC.Fibrolamellar carcinoma: a concise review.Arch Pathol Lab Med2018;142:1141-5

[30] Stipa F,Liau KH.Outcome of patients with fibrolamellar hepatocellular carcinoma.Cancer2006;106:1331-8

[31] Lildballe DL,Poulsen SS,Nexo E.Haptocorrin as marker of disease progression in fibrolamellar hepatocellular carcinoma.Eur J Surg Oncol2011;37:72-9

[32] Fu T,Xu C,Xue L.Imaging findings of fibrolamellar hepatocellular carcinomas on ultrasonography: a comparison with conventional hepatocellular carcinomas.Clin Hemorheol Microcirc2021;77:49-60

[33] Dong Y,Mao F.Imaging features of fibrolamellar hepatocellular carcinoma with contrast-enhanced ultrasound.Ultraschall Med2021;42:306-13

[34] Ichikawa T,Grazioli L,Nalesnik M.Fibrolamellar hepatocellular carcinoma: imaging and pathologic findings in 31 recent cases.Radiology1999;213:352-61

[35] Ganeshan D,Kaseb A,Elsayes KM.Fibrolamellar hepatocellular carcinoma: multiphasic CT features of the primary tumor on pre-therapy CT and pattern of distant metastases.Abdom Radiol (NY)2018;43:3340-8

[36] Liu S,Wang B.Fibrolamellar hepatocellular carcinoma.Am J Gastroenterol2009;104:2617-24; quiz 2625

[37] O'Neill AF,Perez-Atayde AR,Marcus KJ.Fibrolamellar carcinoma: an entity all its own.Curr Probl Cancer2021;45:100770

[38] Ward SC,Tickoo SK,Ladanyi M.Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation.Mod Pathol2010;23:1180-90

[39] Honeyman JN,Robine N.Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.Science2014;343:1010-4 PMCID:PMC4286414

[40] Riggle KM,Scott JD,Riehle KJ.Fibrolamellar hepatocellular carcinoma: mechanistic distinction from adult hepatocellular carcinoma.Pediatr Blood Cancer2016;63:1163-7 PMCID:PMC4877189

[41] Oliveira S, Houseright RA, Korte BG, Huttenlocher A. DnaJ-PKAc fusion induces liver inflammation in a zebrafish model of fibrolamellar carcinoma.Dis Model Mech2020;13:dmm042564

[42] Kakar S,Ho C.Chromosomal changes in fibrolamellar hepatocellular carcinoma detected by array comparative genomic hybridization.Mod Pathol2009;22:134-41

[43] Vyas M,Zhang Y.DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma.Mod Pathol2020;33:648-56

[44] Graham RP,Lam-Himlin D.Molecular testing for the clinical diagnosis of fibrolamellar carcinoma.Mod Pathol2018;31:141-9 PMCID:PMC5758901

[45] Lemekhova A,Polychronidis G.Clinical features and surgical outcomes of fibrolamellar hepatocellular carcinoma: retrospective analysis of a single-center experience.World J Surg Oncol2020;18:93 PMCID:PMC7218513

[46] Schlageter M,D’Angelo S.Histopathology of hepatocellular carcinoma.World J Gastroenterol2014;20:15955-64 PMCID:PMC4239483

[47] Ashtari S,Sharifian A.Hepatocellular carcinoma in Asia: prevention strategy and planning.World J Hepatol2015;7:1708-17 PMCID:PMC4483553

[48] Omata M,Kokudo N.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.Hepatol Int2017;11:317-70 PMCID:PMC5491694

[49] Ozakyol A.Global epidemiology of hepatocellular carcinoma (HCC Epidemiology).J Gastrointest Cancer2017;48:238-40

[50] Zhu RX,Lai CL.Epidemiology of hepatocellular carcinoma in the Asia-Pacific region.Gut Liver2016;10:332-9 PMCID:PMC4849684

[51] Kennedy K,Arora N,Kim HN.Hepatocellular carcinoma among US and non-US-born patients with chronic hepatitis B: risk factors and age at diagnosis.PLoS One2018;13:e0204031 PMCID:PMC6155504

[52] Attwa MH.Guide for diagnosis and treatment of hepatocellular carcinoma.World J Hepatol2015;7:1632-51 PMCID:PMC4483545

[53] Balogh J,Asham EH.Hepatocellular carcinoma: a review.J Hepatocell Carcinoma2016;3:41-53 PMCID:PMC5063561

[54] Roberts LR,Zaiem F. Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatology 2018;67:401-21.[PMID:28859233 DOI:10.1002/hep.29487]

[55] Lim J.Surveillance and diagnosis of hepatocellular carcinoma.Clin Liver Dis (Hoboken)2019;13:2-5 PMCID:PMC6430214

[56] Sherman CB.Utilization and accuracy of biopsy in patients with hepatocellular carcinoma in a community based setting.J Clin Gastroenterol Treat2016;2

[57] Bajenaru N,Săvulescu F,Patrascu T.Hepatic hemangioma -review-.J Med Life2015;8:4-11 PMCID:PMC4564031

[58] Kim KW,Han JK.Hepatic hemangiomas: spectrum of US appearances on gray-scale, power Doppler, and contrast-enhanced US.Korean J Radiol2000;1:191-7 PMCID:PMC2718200

[59] Kim JM,Jang BK.Hemorrhagic hemangioma in the liver: a case report.World J Gastroenterol2015;21:7326-30 PMCID:PMC4476897

[60] Hashemi J,DABAGH K V R. Accuracy of gray-scale and color Doppler sonography in diagnosis of hepatic hemangioma, hepatocellular carcinoma and liver metastasis. IRANIAN JOURNAL OF RADIOLOGY 2008;5:129–34. Available from:https://www.sid.ir/en/journal/ViewPaper.aspx?id=116930[Last accessed on 11 May 2022].

[61] Dietrich CF,Braden B,Ott M.Contrast-enhanced ultrasound of histologically proven liver hemangiomas.Hepatology2007;45:1139-45

[62] Chan YL,Yu SC,Ching AS.Hepatic malignant tumour versus cavernous haemangioma: differentiation on multiple breath-hold turbo spin-echo MRI sequences with different T2-weighting and T2-relaxation time measurements on a single slice multi-echo sequence.Clin Radiol2002;57:250-7

[63] Mogahed MM,Essa B,Ghanem N.Natural history of hepatic hemangiomas as a guide for surgical indication.Egypt Liver Journal2020;10

[64] Venturi A,Vidili G.Diagnosis and management of hepatic focal nodular hyperplasia.J Ultrasound2007;10:116-27 PMCID:PMC3478711

[65] Hsee LC,Koea JB.Focal nodular hyperplasia: what are the indications for resection?.HPB (Oxford)2005;7:298-302 PMCID:PMC2043107

[66] Roncalli M,Tommaso LD.Benign hepatocellular nodules of healthy liver: focal nodular hyperplasia and hepatocellular adenoma.Clin Mol Hepatol2016;22:199-211 PMCID:PMC4946404

[67] Bioulac-sage P.Les angiopoïétines : un rôle physiopathologique dans l’hyperplasie nodulaire focale.Gastroentérologie Clinique et Biologique2004;28:200-1

[68] Burgio M, Ronot M, Salvaggio G, Vilgrain V, Brancatelli G. Imaging of hepatic focal nodular hyperplasia: pictorial review and diagnostic strategy.Semin Ultrasound CT MR2016;37:511-24

[69] Shamsi K,Degryse H.Focal nodular hyperplasia of the liver: radiologic findings.Abdom Imaging1993;18:32-8

[70] Marin D,Federle MP.Focal nodular hyperplasia: typical and atypical MRI findings with emphasis on the use of contrast media.Clin Radiol2008;63:577-85

[71] Krause K.A shifting paradigm in diagnosis and management of hepatic adenoma.Ann Surg Oncol2020;27:3330-8

[72] Vijay A,Khalaf H.Hepatocellular adenoma: an update.World J Hepatol2015;7:2603-9 PMCID:PMC4635146

[73] Barthelmes L.Liver cell adenoma and liver cell adenomatosis.HPB (Oxford)2005;7:186-96 PMCID:PMC2023950

[74] Grazioli L,Brancatelli G,Olivetti L.Hepatic adenomas: imaging and pathologic findings.Radiographics2001;21:877-92; discussion 892

[75] Bieze M,Nio CY.Diagnostic accuracy of MRI in differentiating hepatocellular adenoma from focal nodular hyperplasia: prospective study of the additional value of gadoxetate disodium.AJR Am J Roentgenol2012;199:26-34

[76] Nault JC,Zucman-Rossi J.Hepatocellular benign tumors-from molecular classification to personalized clinical care.Gastroenterology2013;144:888-902

[77] Horn SR,Lehrer EJ.Epidemiology of liver metastases.Cancer Epidemiol2020;67:101760

[78] Marx GM,Goldstein D.Elevated alpha-foetoprotein and hepatic metastases--it's not always what it seems!.Ann Oncol2002;13:167-9

[79] Chen Y,Jian M,He Q.High level of serum AFP is an independent negative prognostic factor in gastric cancer.Int J Biol Markers2015;30:e387-93

[80] Karaosmanoglu AD,Ozmen MN,Karcaaltincaba M.Magnetic resonance imaging of liver metastasis.Semin Ultrasound CT MR2016;37:533-48

[81] Danet IM,Leonardou P.Spectrum of MRI appearances of untreated metastases of the liver.AJR Am J Roentgenol2003;181:809-17

[82] Thian YL,Koh DM.Liver-specific agents for contrast-enhanced MRI: role in oncological imaging.Cancer Imaging2013;13:567-79 PMCID:PMC3893895

[83] Namasivayam S,Saini S.Imaging of liver metastases: MRI.Cancer Imaging2007;7:2-9 PMCID:PMC1804118

[84] Salgia R.The multidisciplinary management of hepatocellular carcinoma.Clin Liver Dis (Hoboken)2021;17:405-8 PMCID:PMC8340356

[85] Mayo SC,Nathan H.Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma: a national perspective.J Am Coll Surg2014;218:196-205 PMCID:PMC4596238

[86] Mavros MN,Hyder O.A systematic review: treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma.J Am Coll Surg2012;215:820-30

[87] Pinna AD,Lee RG.Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation.Hepatology1997;26:877-83 PMCID:PMC3005350

[88] Herman P,Perini MV.Surgical treatment of fibrolamellar hepatocellular carcinoma: an underestimated malignant tumor?.2014;13:618-21

[89] Atienza LG,Mei X.Liver transplantation for fibrolamellar hepatocellular carcinoma: a national perspective.J Surg Oncol2017;115:319-23

[90] Njei B,Ditah I.Prognosis of patients with fibrolamellar hepatocellular carcinoma versus conventional hepatocellular carcinoma: a systematic review and Meta-analysis.Gastrointest Cancer Res2014;7:49-54 PMCID:PMC4007676

[91] Ince V,Ozdemir F,Ara C.Living-Donor liver transplant for fibrolamellar hepatocellular carcinoma with hilar lymph node metastasis: a case report.Exp Clin Transplant2018;

[92] Mergental H,Ericzon BG.Liver transplantation for unresectable hepatocellular carcinoma in normal livers.J Hepatol2012;57:297-305

[93] Gottlieb S,Gliksberg A.Early experiences with triple immunochemotherapy in adolescents and young adults with high-risk fibrolamellar carcinoma.Oncology2021;99:310-7

[94] Kaseb AO,Sahin IH.Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma.Oncology2013;85:197-203 PMCID:PMC3913463

[95] Lamarca A,Fulton A.Fibrolamellar carcinoma: challenging the challenge.Eur J Cancer2020;137:144-7

[96] Patt YZ,Lozano RD.Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.J Clin Oncol2003;21:421-7

[97] Fonseca GM,Coelho FF,Dumarco RB.Downstaging and resection after neoadjuvant therapy for fibrolamellar hepatocellular carcinoma.World J Gastrointest Surg2014;6:107-11 PMCID:PMC4073221

[98] Braybrooke JP,O'Byrne KJ.Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha.Br J Cancer2000;83:219-24 PMCID:PMC2363491

[99] Weeda VB,McCabe AJ.Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma--results and treatment recommendations from the childhood liver tumour strategy group (SIOPEL) experience.Eur J Cancer2013;49:2698-704

[100] Katzenstein HM,Malogolowkin MH.Fibrolamellar hepatocellular carcinoma in children and adolescents.Cancer2003;97:2006-12

[101] O’Neill A,Brugieres L.Gemcitabine and oxaliplatin for the treatment of pediatric patients with hepatocellular carcinoma.2014;61:S128-9

[102] Abou-Alfa GK,Venook AP.Phase II multicenter, open-label study of oral ENMD-2076 for the treatment of patients with advanced fibrolamellar carcinoma.Oncologist2020;25:e1837-45 PMCID:PMC8186410

[103] El Dika I,Venook AP.A multicenter randomized three-arm phase II study of (1) everolimus, (2) estrogen deprivation therapy (EDT) with leuprolide + letrozole, and (3) everolimus + EDT in patients with unresectable fibrolamellar carcinoma.Oncologist2020;25:925-e1603 PMCID:PMC7648371

[104] Faivre S,Boucher E.Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.The Lancet Oncology2009;10:794-800

[105] Mark Yarchoan. DNAJB1-PRKACA fusion kinase peptide vaccine combined with nivolumab and ipilimumab for patients with fibrolamellar hepatocellular carcinoma. Identifier NCT04248569. Available from:https://clinicaltrials.gov/ct2/show/NCT04248569[Last accessed on 11 May 2022].

[106] Allison O’Neill. Checkpoint inhibition in pediatric hepatocellular carcinoma. Identifier NCT04134559. Available from:https://clinicaltrials.gov/ct2/show/NCT04134559?cond=Fibrolamellar+Carcinoma&draw=2&rank=9[Last accessed on 11 May 2022].

[107] Tiao G. Cisplatin and combination chemotherapy in treating children and young adults with hepatoblastoma or liver cancer after surgery. Identifier NCT03533582. Available from: https://clinicaltrials.gov/ct2/show/NCT03533582?cond=Fibrolamellar+Carcinoma&draw=3&rank=11[Last accessed on 11 May 2022].

[108] Aung Naing. Sapanisertib and Ziv-Aflibercept in treating patients with recurrent solid tumors that are metastatic or cannot be removed by surgery. Identifier NCT02159989. Available from: https://clinicaltrials.gov/ct2/show/NCT02159989?cond=Fibrolamellar+Carcinoma&draw=3&rank=12[Last accessed on 11 May 2022].

[109] Peacock J, A Call J, R Olivier K. Radiotherapy for metastatic fibrolamellar hepatocellular carcinoma.Rare Tumors2013;5:e28 PMCID:PMC3804803

[110] Epstein BE,Haulk TL,Order SE.Metastatic nonresectable fibrolamellar hepatoma: prognostic features and natural history.Am J Clin Oncol1999;22:22-8

[111] Raoul JL,Bolondi L,Kloeckner R.Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence.Cancer Treat Rev2019;72:28-36

[112] Somma F,Serra N,Gatta G.Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: the impact of portal vein thrombosis on survival.PLoS One2019;14:e0216935 PMCID:PMC6541348

[113] Aryan M,Qian X.Treatment of advanced hepatocellular carcinoma. Hepatocellular carcinoma - challenges and opportunities of a multidisciplinary approach. IntechOpen; 2021.

[114] Whitlock RS,Patel K.Transarterial radioembolization treatment as a bridge to surgical resection in pediatric hepatocellular carcinoma.J Pediatr Hematol Oncol2021;43:e1181-5

[115] Ljuboja D,Ahmed M.Extrahepatic transarterial radioembolization to treat fibrolamellar hepatocellular carcinoma: a case report.Radiol Case Rep2020;15:2613-6 PMCID:PMC7566208

[116] Mafeld S,Tiniakos D,Manas D.Fibrolamellar hepatocellular carcinoma: treatment with Yttrium-90 and subsequent surgical resection.Cardiovasc Intervent Radiol2018;41:816-20 PMCID:PMC5876273

[117] Aguado A,Towbin AJ.Transarterial radioembolization with yttrium-90 of unresectable primary hepatic malignancy in children.Pediatr Blood Cancer2019;66:e27510

[118] Grandhi MS.Managing fibrolamellar hepatocellular carcinoma.Expert Opinion on Orphan Drugs2016;5:143-52

[119] Sergi C.Fibrolamellar carcinoma: a distinct variant of hepatocellular carcinoma that is still surrounded by unveils mysteries.JCT2014;05:1325-31

[120] Arcement CM,Meza MP.Intrahepatic chemoembolization in unresectable pediatric liver malignancies.Pediatr Radiol2000;30:779-85

[121] Spence RA,Krige JE,Temple-Camp CR.Unresectable fibrolamellar hepatocellular carcinoma treated with intra-arterial lipiodolised doxorubicin-a case report.South African Medical Journal1987;72:701-3

[122] Maniaci V,Rolles K.Fibrolamellar hepatocellular carcinoma: prolonged survival with multimodality therapy.Eur J Surg Oncol2009;35:617-21